‘Made in Chandigarh’ technology to bring down prices of insulin and Hepatitis B vaccine
AdvertisementIf everything at the
Presently India has to depend on patented technology of the foreign countries to produce insulin, streptokinase and hepatitis B etc. With 66 million diabetics and 40 million hepatitis B patients in the country, this will be a major reliever for many.
Pichia is the vector that is currently used in insulin.
"Because Pichia is patented, Indian biotech companies have to pay the inventor, which adds to the cost of the vaccine. Thus, we felt the need to develop new expression systems," Dr
Pichia vector is generally licensed for commercial research for $50,000 with annual maintenance fee of $5000 to $30,000. In case the product is commercialized, the fee is $75,000 plus royalty ranging between 3% and 5%.
The present cost of hepatitis B vaccine in India ranges between Rs 45 (
"So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast. Once the production is scaled up, the production cost is estimated to be around Re 1 per dose, while the lowest production cost reported for Pichia-based system is Rs. 4 per dose and the lowest
Popular on BI
- Elizabeth Holmes ordered dinners for Theranos staff but made sure they weren't delivered until after 8 p.m. so they worked late: book
- 2,000 years before 'manscaping' and smooth armpits, the Romans were seriously into hair removal, archaeological findings show
- Some people are apparently ditching their iPhones for a foldable Razr model. Yes, the kind that was popular 20 years ago.
- Explained: Why Apple's new VR headset is the talk of the town despite being priced 3X more than Meta Quest Pro
- Aditya Birla Group to take on Tata, Reliance now in the branded jewellery space
- Indian homes expected to make half their payments digitally in 3 years
- Vision Pro to iOS 17: Apple’s top six announcements at WWDC 2023
- New Apple iOS: If you have these devices, it might be time to upgrade